Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Longeveron (NASDAQ: LGVN) will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025 in New York.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Longeveron (NASDAQ: LGVN) will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025 in New York.
Management will hold one-on-one investor meetings during the conference to discuss the company's clinical-stage cellular therapy programs for rare pediatric and aging-related conditions.
Details
News Market Reaction – LGVN
On Oct 6, the day this news came out, LGVN closed 0.28% above the previous close.
Data tracked by StockTitan Argus for the Oct 6 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that it will participate in the 4th Annual ROTH Healthcare Opportunities Conference.
Longeveron management will host one-on-one meetings with investors at the conference to be held October 9, 2025 in New York.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Derek Cole
Investor Relations Advisory Solutions
derek.cole@iradvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.